APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Aptevo Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.60−0.02 (-1.23%)
Close on Oct 19, 2026
- Market cap
- $1.91M
- P/E (TTM)
- –
- Dividend yield
- –
Aptevo Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Product sales | $32.40M | $23.10M | $10.95M | – | – | 99.9% | +40.3% |
| Collaborations | – | – | $3.71M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Aptevo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.